Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity.

Autor: Allegretti JR; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. jallegretti@bwh.harvard.edu., Kassam Z; Finch Therapeutics Group, Somerville, MA, USA., Hurtado J; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA., Marchesi JR; Division of Integrative Systems Medicine and Digestive Disease, Faculty of Medicine, Imperial College London, London, UK., Mullish BH; Division of Integrative Systems Medicine and Digestive Disease, Faculty of Medicine, Imperial College London, London, UK., Chiang A; Division of Gastroenterology, Jefferson University, Philadelphia, PA, USA., Thompson CC; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA., Cummings BP; Department of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA. bpc68@cornell.edu.
Jazyk: angličtina
Zdroj: Hormones (Athens, Greece) [Hormones (Athens)] 2021 Mar; Vol. 20 (1), pp. 209-211. Date of Electronic Publication: 2021 Jan 09.
DOI: 10.1007/s42000-020-00265-z
Abstrakt: Background: Fecal microbiota transplantation (FMT) has been studied for the treatment of metabolic syndrome with varying success. However, the possibility of utilizing FMT to prevent metabolic syndrome is to date unknown.
Methods: Secondary analysis of a previously published double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients was conducted. Post-prandial glucose and insulin levels were measured (NCT02741518).
Results: A total of 22 patients were enrolled, 11 in each arm. There were no baseline differences in the area under the curve (AUC) of glucose or insulin in the FMT group compared to placebo. There was a significant change in glucose AUC at week 12 compared to baseline, and in the insulin AUC at week 6 compared to baseline in the FMT group vs. placebo (change in glucose AUC (mg/dl × 60 min): 579 vs 1978, p = 0.03) (change in insulin AUC (μU/ml × 60 min): 137 vs 2728, p = 0.01).
Conclusions: These data suggest that FMT may have a potential role in preventing the development of metabolic syndrome in patients with obesity.
Databáze: MEDLINE
Externí odkaz: